AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02573467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Trial: NCT00335192
Drug: Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
Trial: NCT04328285
Drug: Placebo of LPV/r Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
Trial: NCT00167882
Drug: 5-aminosalicylate (Pentasa, Ferring)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01560988
Drug: Borage and Echium Seed Oils
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
Trial: NCT02056288
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
Trial: NCT01557816
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
Trial: NCT01557816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for seven days given BID during either of the 2 treatment periods.
Trial: NCT00425360
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01243125
Drug: NVC-422, 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Trial: NCT01243125
Drug: Sterile normal saline, 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Trial: NCT04286503
Drug: basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic treatment
Trial: NCT00351104
Drug: Ketoprofen Topical Patch 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03319121
Drug: Empirical therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
Trial: NCT03319121
Drug: Guided therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
Trial: NCT02746380
Drug: Humira®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab
Trial: NCT02403037
Drug: Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
RxNorm normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Trial: NCT02151253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Trial: NCT02070991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00189384
Drug: ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079870
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous (s.c. - under the skin) injection
Trial: NCT02523898
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 8 weeks plus 100 mg clomiphene for 5 days
Trial: NCT01899703
Drug: GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
Trial: NCT01899703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
Trial: NCT03970798
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
Trial: NCT03970798
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
Trial: NCT02981498
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT03682120
Drug: MF59
RxNorm normalized name: vaccine adjuvant emulsion MF59C.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Trial: NCT04797793
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Trial: NCT04797793
Drug: Differin® Gel (Adapalene 0.1%, Galderma)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Trial: NCT02678260
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
Trial: NCT02659228
Drug: Anesthetics, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
Trial: NCT00870571
Drug: NorvasC® 10 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
Trial: NCT00379574
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 750mg/m2 day 1, every 2 weeks
Trial: NCT00379574
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 50 mg/m2 day 1, every 2 weeks
Trial: NCT00379574
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 100 mg days 1-5, every 2 weeks
Trial: NCT03855280
Drug: APVO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
Trial: NCT01847157
Drug: Epidermis anesthesia
RxNorm normalized name: Staphylococcus epidermidis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Trial: NCT01847157
Drug: sham anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Trial: NCT00083447
Drug: TransMID™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02755090
Drug: IV Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192697
Drug: ASP8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00610948
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00610948
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04059094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation solution
Trial: NCT00757731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard capsule
Trial: NCT00005774
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
Trial: NCT00005774
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant according to current center practice, only after initiation of mechanical ventilation.
Trial: NCT01722071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
Trial: NCT03780725
Drug: [89Zr]Zr-BI 754111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT02968927
Drug: 2HRbZE/4HRb
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00294788
Drug: PCC® (Lactobacillus fermentum VRI 003)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03888079
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
Trial: NCT03888079
Drug: general anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotracheal intubation, intravenous narcotic agents, and inhaled agents
Trial: NCT01851369
Drug: TRC102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
Trial: NCT03066076
Drug: Antithyroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug
Trial: NCT02318277
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 administered intravenously (IV) every two weeks (q2w)
Trial: NCT02318277
Drug: INCB024360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB024360: Oral daily dosing
Trial: NCT00179179
Drug: nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
Trial: NCT00002835
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002835
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002835
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01047397
Drug: 1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, 50mg, 100mg
Trial: NCT01047397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00581997
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00581997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00167947
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Trial: NCT02624089
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
Trial: NCT02069184
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
Trial: NCT01609140
Drug: MPSK3169A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen A, repeating subcutaneous injections every 4 weeks
Trial: NCT01609140
Drug: MPSK3169A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen E, repeating subcutaneous injections every 4 weeks
Trial: NCT01609140
Drug: MPSK3169A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen D, repeating subcutaneous injections every 4 weeks
Trial: NCT01609140
Drug: MPSK3169A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen C, repeating subcutaneous injections every 4 weeks
Trial: NCT01609140
Drug: MPSK3169A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose regimen B, repeating subcutaneous injections every 4 weeks
Trial: NCT01609140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating subcutaneous injections of placebo every 4 weeks
Trial: NCT01799278
Drug: MLN8237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
Trial: NCT02129556
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
Trial: NCT01198548
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01198548
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04374552
Drug: Hydroxychloroquine sulfate &Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug - Hydroxychloroquine sulfate \&Azithromycin
Trial: NCT04374552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug - placebo
Trial: NCT02269488
Drug: MEDI3250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3250
Trial: NCT00306722
Drug: AQUAVAN® (fospropofol disodium) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01101048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
Trial: NCT02037074
Drug: Drug: EVP-6308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1, 2, 3
Trial: NCT02037074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 4
Trial: NCT00667966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/20 mg placebo in sequence in respective arm
Trial: NCT00991562
Drug: IMGN901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation study. dosing on days 1, 8 and 15 every 28 days
Trial: NCT03739554
Drug: CYC065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01610388
Drug: 500mg IV GSK1322322/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg IV
Trial: NCT01610388
Drug: 1000mg oral GSK1322322/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg oral
Trial: NCT01610388
Drug: 1000mg IV GSK1322322/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV
Trial: NCT01610388
Drug: 1500mg oral GSK1322322/placebo dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg oral
Trial: NCT01610388
Drug: 1500mg IV GSK1322322/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg IV
Trial: NCT01610388
Drug: 2000mg IV GSK1322322J/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000mg IV
Trial: NCT01610388
Drug: 3000mg IV GSK1322322J/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000mg IV
Trial: NCT01610388
Drug: 1000mg IV GSK1322322J/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV
Trial: NCT00003456
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00656474
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo gel on Day 1, 3 and 5 post ablation.
Trial: NCT00656474
Drug: GLYC-101 gel (1.0 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration on Day 1, 3 and 5 post laser ablation.
Trial: NCT01941641
Drug: neoadjuvant FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01941641
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01503801
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
Trial: NCT02194491
Drug: ASP3662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03197155
Drug: Direct Acting Antivirals against hepatitis C virus infection
RxNorm normalized name: hepatitis C virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
Trial: NCT01105130
Drug: Oral L-Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally 3 capsules ArginMax and 3 Placebo capsules
Trial: NCT01105130
Drug: Oral L-Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 6 capsules of ArginMax twice daily
Trial: NCT03298061
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
Trial: NCT03521336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline，Sham operation
Trial: NCT01521364
Drug: Addition of different doses of clarithromycin.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks.
Trial: NCT02175758
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF administered orally once daily
Trial: NCT03514537
Drug: Liberase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberase TM for use to enzymatically isolate cellular stromal vascular fraction